Autoantibodies in Moroccan patients with type 1 diabetes: Which one to choose?

被引:0
|
作者
El Guendouz, Faycal [1 ]
Derrou, Sara [1 ]
Benabdelfedil, Yousra [1 ]
Ouleghzal, Hassan [1 ]
Safi, Somaya [1 ]
机构
[1] Sidi Mohamed Ben Abdellah Univ, Moulay Ismail Mil Hosp Meknes, Fes, Morocco
来源
CLINICAL DIABETOLOGY | 2021年 / 10卷 / 05期
关键词
Moroccan type 1 diabetes; pancreatic autoimmunity; pancreatic autoantibodies; GADA; IA2A; ICA; BETA-CELL FUNCTION; ANTIBODIES; IA-2; GAD;
D O I
10.5603/DK.a2021.0030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Immunological investigations are intended for diagnosing T1D in atypical clinical presentation, also exploring the predisposition to T1D in a context of multiple autoimmune disorders or among the siblings of a patient with type 1 diabetes. While the diagnosing or the screening of T1D using five antibodies presents high expenses especially in emerging countries, it is for interest to determine their prevalence in order to choose the most frequent and most relevant. The aim of our study is to determine the prevalence of antibodies in Moroccan population. Methods. We investigated 62 T1D patients, the prevalence of autoantibodies was 74% for glutamic acid decarboxylase 65 auto-antibody (GADA), 46% for insulinoma-associated protein 2 autoanti body (IA2A), and 3% for islet cell antibodies (ICA). GADA and/or IA2A were reported in all patients (100%). The GADA frequency was neither associated with the duration of diabetes nor the age of patients. Results. Finally, GADAs are by far the best markers for T1D, IA2As complements GADAs and increases the diagnostic sensitivity for detection of pancreatic autoimmunity and ICA should be abandoned because of its low prevalence.
引用
收藏
页码:403 / 406
页数:4
相关论文
共 50 条
  • [1] Which One to Choose?
    籍万杰
    英语知识, 1999, (07) : 14 - 14
  • [2] Significance of lactoferrin autoantibodies in patients with type 1 diabetes
    Derevyanko, O. S.
    Nikonova, T. V.
    Pekareva, E. V.
    Ilyin, A. V.
    Smirnova, O. M.
    DIABETOLOGIA, 2012, 55 : S196 - S196
  • [3] Controlled attenuation parameter for the assessment of fatty liver in patients with type 1 diabetes mellitus: which cutoffs to choose?
    Grzelka-Wozniak, Agata
    Uruska, Aleksandra
    Szymanska-Garbacz, Elektra
    Araszkiewicz, Aleksandra
    Jablkowski, Maciej
    Czupryniak, Leszek
    Zozulinska-Ziolkiewicz, Dorota
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2024, 134 (01):
  • [4] Autoantibodies in type 1 diabetes
    Taplin, Craig E.
    Barker, Jennifer M.
    AUTOIMMUNITY, 2008, 41 (01) : 11 - 18
  • [5] Autoantibodies in Type 1 diabetes
    Heras, Panagiotis
    Mantzioros, Marios
    Mendrinos, Dimitrios
    Heras, Vasilios
    Hatzopoulos, Antonios
    Xourafas, Vasilios
    Kritikos, Konstantinos
    Karagiannis, Stefanos
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (02) : E40 - E42
  • [6] Autoantibodies in type 1 diabetes
    Schmidt, KD
    Valeri, C
    Leslie, RDG
    CLINICA CHIMICA ACTA, 2005, 354 (1-2) : 35 - 40
  • [7] Organ specific autoantibodies in patients with type 1 diabetes, LADA and type 2 diabetes
    Schloot, N. C.
    Hawa, M. I.
    Scherbaum, W. A.
    Pozzilli, P.
    Leslie, R.
    Seissler, J.
    DIABETOLOGIA, 2008, 51 : S235 - S235
  • [8] TSH receptor autoantibodies in patients with type 1 diabetes mellitus
    Witkowski, D.
    Piontek, E.
    Moszczynska, E.
    Janas, R.
    DIABETOLOGIA, 2009, 52 : S383 - S384
  • [9] Autoantibodies to thyroid peroxidase in patients with type 1 diabetes in Taiwan
    Chang, CC
    Huang, CN
    Chuang, LM
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 139 (01) : 44 - 48
  • [10] Serological tests for celiac disease in Moroccan patients with type 1 diabetes
    Bourhanbour, Asmaa Drissi
    Ouadghiri, Sanae
    Benseffaj, Nadia
    Essakalli, Malika
    PAN AFRICAN MEDICAL JOURNAL, 2016, 24